CL2002001701A1 - Uso de al menos un compuesto seleccionado entre melatonina, agentes melatoninergicos, agonistas y antagonistas de melatonina, en una cantidad de 0,0025-50 mg, para preparar un medicamento util para el tratamiento y mejora de la calidad repadora del sueno. - Google Patents

Uso de al menos un compuesto seleccionado entre melatonina, agentes melatoninergicos, agonistas y antagonistas de melatonina, en una cantidad de 0,0025-50 mg, para preparar un medicamento util para el tratamiento y mejora de la calidad repadora del sueno.

Info

Publication number
CL2002001701A1
CL2002001701A1 CL2002001701A CL2002001701A CL2002001701A1 CL 2002001701 A1 CL2002001701 A1 CL 2002001701A1 CL 2002001701 A CL2002001701 A CL 2002001701A CL 2002001701 A CL2002001701 A CL 2002001701A CL 2002001701 A1 CL2002001701 A1 CL 2002001701A1
Authority
CL
Chile
Prior art keywords
melatonin
antagonists
sleep
improvement
treatment
Prior art date
Application number
CL2002001701A
Other languages
English (en)
Inventor
Zisapel Nava
Original Assignee
Neurim Pharmaceuticals 1991 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11075696&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2002001701(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurim Pharmaceuticals 1991 Ltd filed Critical Neurim Pharmaceuticals 1991 Ltd
Publication of CL2002001701A1 publication Critical patent/CL2002001701A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Uso de al menos un compuesto seleccionado entre melatonina, otros agentes melatoninergicos, agonistas y antagonistas de la melatonina para el tratamiento y la mejora de la calidad reparadora del sueño en insomnio primario; y composición farmacéutica que comprende al compuesto.
CL2002001701A 2001-08-14 2002-07-31 Uso de al menos un compuesto seleccionado entre melatonina, agentes melatoninergicos, agonistas y antagonistas de melatonina, en una cantidad de 0,0025-50 mg, para preparar un medicamento util para el tratamiento y mejora de la calidad repadora del sueno. CL2002001701A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL144900A IL144900A (en) 2001-08-14 2001-08-14 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs

Publications (1)

Publication Number Publication Date
CL2002001701A1 true CL2002001701A1 (es) 2010-06-25

Family

ID=11075696

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2002001701A CL2002001701A1 (es) 2001-08-14 2002-07-31 Uso de al menos un compuesto seleccionado entre melatonina, agentes melatoninergicos, agonistas y antagonistas de melatonina, en una cantidad de 0,0025-50 mg, para preparar un medicamento util para el tratamiento y mejora de la calidad repadora del sueno.

Country Status (35)

Country Link
US (1) US8962024B2 (es)
EP (2) EP1441702B1 (es)
JP (1) JP2005501095A (es)
KR (1) KR20040032917A (es)
CN (1) CN100453078C (es)
AR (1) AR034975A1 (es)
AU (1) AU2002326114C1 (es)
BR (1) BR0211855A (es)
CA (1) CA2454699C (es)
CL (1) CL2002001701A1 (es)
CR (1) CR7271A (es)
CY (2) CY1118924T1 (es)
DK (2) DK1441702T3 (es)
EA (1) EA200400302A1 (es)
ES (2) ES2882584T3 (es)
GT (1) GT200200164A (es)
HK (1) HK1066161A1 (es)
HU (1) HU230786B1 (es)
IL (1) IL144900A (es)
IS (1) IS3004B (es)
JO (1) JO3446B1 (es)
LT (1) LT1441702T (es)
MX (1) MXPA04001372A (es)
NO (1) NO334788B1 (es)
NZ (1) NZ531318A (es)
PA (1) PA8552301A1 (es)
PE (1) PE20030331A1 (es)
PL (1) PL367872A1 (es)
PT (2) PT3103443T (es)
RU (1) RU2560840C2 (es)
SI (1) SI1441702T1 (es)
UA (1) UA87262C2 (es)
UY (1) UY27401A1 (es)
WO (1) WO2003015690A2 (es)
ZA (1) ZA200402005B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
IL149377A (en) * 2002-04-28 2012-10-31 Neurim Pharma 1991 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
AR056076A1 (es) * 2005-09-20 2007-09-19 Takeda Pharmaceutical Agente profilactico o terapeutico para el desorden de sueno
US20070088079A1 (en) * 2005-09-20 2007-04-19 Takeda Pharmaceutical Company Limited Prophylactic or therapeutic agent for sleep disorder
JP2009536667A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド ５ｈｔ受容体介在性の神経新生
EP2124907B1 (en) 2007-03-19 2018-05-30 Vita Sciences, Llc Transdermal patch and method for delivery of vitamin b12
WO2008122102A1 (en) * 2007-04-05 2008-10-16 Iomedix Development International Srl Melatonin-based composition for improved sleep
US20080248106A1 (en) 2007-04-05 2008-10-09 Marvin Heuer Melatonin-based composition for improved sleep
WO2012103411A2 (en) * 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
EP3777842A1 (en) 2016-10-31 2021-02-17 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same
US10849856B2 (en) 2016-10-31 2020-12-01 Neurim Pharmaceuticals Ltd. Melatonin mini-tablets and method of manufacturing the same

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3126375A (en) 1964-03-24 Chioacyl
US2789118A (en) 1956-03-30 1957-04-16 American Cyanamid Co 16-alpha oxy-belta1, 4-pregnadienes
US2990401A (en) 1958-06-18 1961-06-27 American Cyanamid Co 11-substituted 16alpha, 17alpha-substituted methylenedioxy steroids
US3048581A (en) 1960-04-25 1962-08-07 Olin Mathieson Acetals and ketals of 16, 17-dihydroxy steroids
US3749712A (en) 1970-09-25 1973-07-31 Sigma Tau Ind Farmaceuti Triamcinolone acetonide esters and process for their preparation
SE378110B (es) 1972-05-19 1975-08-18 Bofors Ab
SE378109B (es) 1972-05-19 1975-08-18 Bofors Ab
US3996359A (en) 1972-05-19 1976-12-07 Ab Bofors Novel stereoisomeric component A of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steroid 21-acylates, compositions thereof, and method of treating therewith
JPS6045513A (ja) * 1983-05-18 1985-03-12 モナシユ　ユニバ−シテイ 身体行動および機能の日周期の不調を軽減する薬剤
US4600723A (en) * 1983-05-18 1986-07-15 Monash University Method for minimizing disturbances in circadian rhythms of bodily performance and function
DE3466215D1 (en) 1983-05-18 1987-10-22 Univ Monash The use of melatonin for the manufacture of a medicament
US5151446A (en) 1989-09-25 1992-09-29 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
FR2658818B1 (fr) 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5707652A (en) 1990-12-04 1998-01-13 State Of Oregon Methods of treating circadian rhythm phase disorders
US5591768A (en) 1990-12-04 1997-01-07 State Of Oregan, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University Methods for treating circadian rhythm phase disturbances
ATE181670T1 (de) 1991-05-09 1999-07-15 Neurim Pharma 1991 Melatonin enthaltende arzneimittel
IT1251544B (it) 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
FR2680507B1 (fr) 1991-08-23 1993-10-08 Adir Cie Nouvelles naphtylethylurees et naphtylethylthiourees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
ATE141051T1 (de) * 1992-04-07 1996-08-15 Neurim Pharma 1991 Verwendung von melatonin zur herstellung eines arzneimittels zur behandlung der gutartigen prostatahyperplasie
US5449683A (en) 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin
IL103411A (en) 1992-10-11 1996-11-14 Neurim Pharma 1991 Melatonin Controlled Pharmacy Preparation for the Correction of Melatonin Deficiency or Distortion in Melatonin in Human Plasma
WO1994013676A1 (en) 1992-12-17 1994-06-23 Pfizer Inc. Pyrrolopyrimidines as crf antagonists
WO1994013661A1 (en) 1992-12-17 1994-06-23 Pfizer Inc. Substituted pyrazoles as crf antagonists
TW336932B (en) 1992-12-17 1998-07-21 Pfizer Amino-substituted pyrazoles
DK0674624T3 (da) 1992-12-17 1999-09-13 Pfizer Pyrazoler med CRF-antagonistisk aktivitet
TW370529B (en) 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
WO1995003043A1 (en) 1993-07-26 1995-02-02 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University Sustained release oral compositions containing melatonin
US5654325A (en) * 1993-11-18 1997-08-05 Eli Lilly And Company Melatonin derivatives for use in treating sleep disorders
US5403851A (en) 1994-04-05 1995-04-04 Interneuron Pharmaceuticals, Inc. Substituted tryptamines, phenalkylamines and related compounds
US6469044B1 (en) 1995-02-01 2002-10-22 Neurim Pharmaceuticals (1991) Ltd. Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
US5688520A (en) * 1995-03-29 1997-11-18 Minnesota Mining And Manufacturing Company Transmucosal delivery of melatonin for prevention of migraine
EP0748627A3 (en) 1995-06-14 1997-05-21 Lilly Co Eli Melatonin agonists for the treatment of benign forms of hyperplasia of the prostate
NO981489L (no) * 1995-10-03 1998-05-22 Interneuron Pharma Blandinger av melatonin og analgetika samt anvendelser derav
ATE265209T1 (de) * 1996-07-17 2004-05-15 Merck & Co Inc Änderung des zirkadischen rhythmus mit nicht- peptidischen neurokinin-1 rezeptor antagonisten
US5776969A (en) 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
US5826408A (en) * 1997-05-08 1998-10-27 Riverwood International Corporation Rotary flap tucker for a cartoning machine
US6472421B1 (en) 1998-11-13 2002-10-29 Nymox Corporation Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an HMG CoA reductase inhibitor
PT1272177E (pt) * 2000-01-05 2007-07-11 Neurim Pharma 1991 Método e formulação para o tratamento da resistência aos antihipertensos e condições associadas.
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
US6703412B1 (en) 2002-09-27 2004-03-09 Holly A. Rosenthal Method of treating sleeplessness with melatonin on an acute basis
EP2760523A1 (en) 2011-09-27 2014-08-06 Ibis Medical Inc. Intragastric implant devices

Also Published As

Publication number Publication date
US20040248966A1 (en) 2004-12-09
AU2002326114C1 (en) 2019-03-21
CY1118924T1 (el) 2018-01-10
IL144900A0 (en) 2002-06-30
PT1441702T (pt) 2017-06-02
HUP0401042A2 (hu) 2004-08-30
CY1124763T1 (el) 2022-07-22
PA8552301A1 (es) 2003-06-30
ES2882584T3 (es) 2021-12-02
IS7136A (is) 2004-01-30
CN100453078C (zh) 2009-01-21
EP1441702A2 (en) 2004-08-04
UY27401A1 (es) 2003-02-28
EA200400302A1 (ru) 2004-10-28
ES2626591T3 (es) 2017-07-25
AR034975A1 (es) 2004-03-24
NO334788B2 (no) 2014-05-26
PL367872A1 (en) 2005-03-07
CA2454699C (en) 2012-03-27
DK1441702T3 (en) 2017-06-06
CR7271A (es) 2004-05-17
NO334788B1 (no) 2014-05-26
NO20040087L (no) 2004-02-19
UA87262C2 (uk) 2009-07-10
DK3103443T3 (da) 2021-08-30
CN1541092A (zh) 2004-10-27
NZ531318A (en) 2005-08-26
PE20030331A1 (es) 2003-06-27
EP1441702B1 (en) 2017-05-10
GT200200164A (es) 2003-09-26
EP3103443A1 (en) 2016-12-14
IL144900A (en) 2013-12-31
EP1441702A4 (en) 2007-09-26
MXPA04001372A (es) 2005-06-06
CA2454699A1 (en) 2003-02-27
HUP0401042A3 (en) 2009-07-28
KR20040032917A (ko) 2004-04-17
US8962024B2 (en) 2015-02-24
JP2005501095A (ja) 2005-01-13
IS3004B (is) 2018-09-15
WO2003015690A2 (en) 2003-02-27
AU2002326114A1 (en) 2003-03-03
HK1066161A1 (en) 2005-03-18
LT1441702T (lt) 2017-06-12
RU2011131532A (ru) 2013-03-27
WO2003015690B1 (en) 2004-03-11
JO3446B1 (ar) 2020-07-05
WO2003015690A3 (en) 2003-09-25
SI1441702T1 (sl) 2017-08-31
RU2560840C2 (ru) 2015-08-20
BR0211855A (pt) 2004-09-21
PT3103443T (pt) 2021-08-12
AU2002326114B2 (en) 2007-03-08
HU230786B1 (en) 2018-05-02
ZA200402005B (en) 2005-07-27
EP3103443B1 (en) 2021-06-30

Similar Documents

Publication Publication Date Title
CY1118924T1 (el) Μεθοδος για θεραπεια της πρωτοπαθους αϋπνιας
ES2167061T3 (es) Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino.
HN2002000275A (es) Derivados de 1,8 naftiridina y su uso para el tratamiento de diabetes y trastornos relacionados
BR0107869A (pt) Composições farmacêuticas eletrogiradas
BG105568A (en) Pharmaceutical compositions for modified release of an insulin sensitiser and another antidiabetic agent
ES2162517T3 (es) Composicion farmaceutica que comprende una combinacion de metformin y fibrato y su uso en la preparacion de medicamentos destinados a reducir la hiperglicemia.
CL2008003941A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden compulsivo obsesivo.
AP2001002129A0 (en) 5HT1 receptor agonists and metoclopramide for the treatment of migrane.
ATE260650T1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
ES2190205T3 (es) Combinacion para el tratamiento de la dependencia del alcohol que contiene un antagonista opioide y un modulador del complejo receptor de nmda.
ATE333896T1 (de) Vaskularisierungsinhibitoren
AR024998A1 (es) Nuevos retinoides para el tratamiento del enfisema
SE0102055D0 (sv) New Compounds
AR018162A1 (es) Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica
TW200501948A (en) Composition for improving cognition and memory
AR023687A1 (es) Una composicion para el tratamiento de desordenes de la retina externa y el uso de un antagonista de glutamato para la manufactura de un medicamento parael tratamiento de desordenes de la retina externa
AR024232A1 (es) Bromhidrato de eletriptan monohidratado, composicion farmaceutica, su uso en la preparacion de medicamentos y procedimiento para su preparacion
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía
AR043016A2 (es) Un compuesto antimigranico eletriptan y composicion farmaceutica que lo contiene
AR033807A1 (es) Uso de (r)-(-)-2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y de sus sales aceptables para uso fisiologico, y las composiciones farmaceuticas que contiene estos compuestos
AR014082A1 (es) Concentrado oral de sertralina
SE0000303D0 (sv) Novel compounds
HUT77175A (hu) Szelegilin alkalmazása epilepsziás betegségek kezelésére használható gyógyszerkészítmények előállítására és szelegilint tartalmazó epilepsziaellenes gyógyszerkészítmények
AR015976A1 (es) Composiciones que contienen agonistas de h2 de histamina para el tratamiento del ojo seco y el uso de las mismas en la manufactura de un medicamento
AR026756A1 (es) Nuevas combinaciones terapeuticas (s)-2-bencilamino-metil)-2,3,8,9-tetrahidro-7h-1,4-dioxino[2,3-e]indol-8-ona y neuroleticos para el tratamiento oprevencion de desordenes psicoticos